Balloon dilation of the eustachian tube for dilatory dysfunction: A randomized controlled trial
Objectives/Hypothesis To assess balloon dilation of the Eustachian tube with Eustachian tube balloon catheter in conjunction with medical management as treatment for Eustachian tube dilatory dysfunction. Study Design In this prospective, multicenter, randomized, controlled trial, we assigned, in a 2...
Saved in:
Published in: | The Laryngoscope Vol. 128; no. 5; pp. 1200 - 1206 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Wiley Subscription Services, Inc
01-05-2018
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Objectives/Hypothesis
To assess balloon dilation of the Eustachian tube with Eustachian tube balloon catheter in conjunction with medical management as treatment for Eustachian tube dilatory dysfunction.
Study Design
In this prospective, multicenter, randomized, controlled trial, we assigned, in a 2:1 ratio, patients age 22 years and older with Eustachian tube dilatory dysfunction refractory to medical therapy to undergo balloon dilation of the Eustachian tube with balloon catheter in conjunction with medical management or medical management alone.
Methods
The primary endpoint was normalization of tympanogram at 6 weeks. Additional endpoints were normalization of Eustachian Tube Dysfunction Questionaire‐7 symptom scores, positive Valsalva maneuver, mucosal inflammation, and safety.
Results
Primary efficacy results demonstrated superiority of balloon dilation of the Eustachian tube with balloon catheter + medical management compared to medical management alone. Tympanogram normalization at 6‐week follow‐up was observed in 51.8% (72/139) of investigational patients versus 13.9% (10/72) of controls (P < .0001). Tympanogram normalization in the treatment group was 62.2% after 24 weeks. Normalization of Eustachian Tube Dysfunction Questionaire‐7 Symptom scores at 6‐week follow‐up was observed in 56.2% (77/137) of investigational patients versus 8.5% (6/71) controls (P < .001). The investigational group also demonstrated substantial improvement in both mucosal inflammation and Valsalva maneuver at 6‐week follow‐up compared to controls. No device‐ or procedure‐related serious adverse events were reported for those who underwent balloon dilation of the Eustachian tube.
Conclusions
This study demonstrated superiority of balloon dilation of the Eustachian tube with balloon catheter + medical management compared to medical management alone to treat Eustachian tube dilatory dysfunction in adults.
Level of Evidence
1b. Laryngoscope, 128:1200–1206, 2018 |
---|---|
Bibliography: | The authors have no other funding, financial relationships, or conflicts of interest to disclose. c d.p. is an employee of Depuy Synthes and Johnson & Johnson Medical Devices Companies. j l is a consultant for Acclarent and Intersect ENT. . p r s are consultants for Acclarent. and previously served on the Acclarent Surgeons Advisory Board. was a consultant for Acclarent during part of the study. w m.d. Funding for this trial was provided by Acclarent, Inc. Editorial support in the form of medical writing, assembling tables and creating high‐resolution images based on authors detailed directions, collating author comments, copyediting, fact checking, and referencing was provided by Cactus Communications funded by Acclarent, Inc. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 |
ISSN: | 0023-852X 1531-4995 |
DOI: | 10.1002/lary.26827 |